Urinary Tract Infection Testing Market Expected to Reach $1 Billion by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Urinary Tract Infection Testing Market," The urinary tract infection testing market was valued at $574.00 million in 2021, and is estimated to reach $1 billion by 2031, growing at a CAGR of 6.2% from 2022 to 2031.

A urinary tract infection (UTI) is an infection in any region of the urinary system. The urinary system consists of the kidneys, ureters, bladder, and urethra. Most infections affect the lower urinary tract, specifically the bladder and urethra. Women are at a higher risk of acquiring a UTI than males. An infection that is restricted to the bladder can be uncomfortable and irritating. Hence, if a UTI spreads to the kidneys, major health concerns might occur.

A urine test is known as a urinalysis and is used to identify and treat a variety of illnesses, including diabetes, renal disease, and urogenital infections. A urinalysis involves examining the color, volume, and composition of urine. Nearly 150 million people worldwide suffer from urinary tract infections, one of the most prevalent bacterial infections. Most urinary tract infections are brought on by bacteria, viruses, and fungi, and they usually affect the urinary tract. Several bacteria, including Escherichia coli, klebsiella species, pseudomonas aeruginosa, Proteus species, and enterococcus species, are responsible for urinary tract infections. Furthermore, one of the main factors driving the market growth includes the rising prevalence of urinary tract infections (UTIs) in developing countries.

UTIs are difficult to diagnose, not only because of the enormous number of infections that occur each year but also because the diagnosis of UTI is not always simple. False UTI test findings, however, may hamper market expansion. Rapid testing or dipstick tests may yield false-positive results in one out of every five patients. The availability of at-home sample collection kits and self-testing kits for UTI testing is expected to provide abundant growth prospects for leading market players.

The rising prevalence, recurrence rates, and high antibiotic resistance among uropathogens, and urinary tract infections (UTIs) have become a major public health concern worldwide. Traditional methods of diagnosis, such as urine culture and microscopy, are time-consuming and arduous, but alternative approaches, such as ELISA, PCR, Raman spectroscopy, MALDI-TOF mass spectroscopy, flow cytometry, nucleic-acid-based diagnostics, and isothermal calorimetry, are quick but require well-trained experts and expensive instruments. Therefore, there is a pressing need for a quick, portable, highly sensitive, and cost-effective diagnostic instrument. Biosensors are acknowledged as an efficient and emerging technology that provides an early and precise identification of uropathogens, which is critical in the therapy of UTIs. For an early-stage diagnosis, which is necessary for individualized healthcare management, biosensors are increasingly being used as sensitive, focused, and reasonably priced analytical tools. Nanotechnology has revolutionized and improved the sensing area through efficient device integration, sensing unit manufacture, interface, packaging, and performance, allowing biosensors to be tailored to the needs of illness management and patient disease profiles in an individualistic manner.

The urinary tract infection testing market share is segmented on the basis of infection type, test type, end user, test kit, and region. By infection type, it is classified into urethritis, cystitis, and pyelonephritis. By test type, it is divided into urinalysis, urine cultures, and susceptibility testing. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players profiled in the urinary tract infection testing market growth report include F. Hoffmann-La Roche Ltd, Stryker, Abbott, Siemens, Sysmex Corporation, Cardinal Health, Danaher, Quidel, Bio-Rad Laboratories, Inc., and ACON Labs.

The report offers a comprehensive analysis of the global urinary tract infection testing market size by thoroughly studying different aspects of the market including major segments, market statistics, market dynamics, regional market outlook, investment opportunities, and top players working towards the growth of the market. The report highlights the present scenario and upcoming urinary tract infection testing market trends & developments that are contributing toward the growth of the market. Moreover, restraints and challenges that hold power to obstruct the market growth are also profiled in the report along with Porter’s five forces analysis of the market to elucidate factors such as competitive landscape, bargaining power of buyers and suppliers, threats of new players, and the emergence of substitutes in the market.

Impact of COVID-19 on the Global Urinary Tract Infection Testing Industry

• Lower urinary tract symptoms may be severe, depending on the severity of the COVID-19 infection. Several studies have found white blood cells and hematuria in the urine of a COVID-19 patient
• The unexpected rise in coronavirus-infected individuals restricted access to other primary care services, and non-COVID-19-related diagnoses such as urinary tract infections fell dramatically
• The COVID-19 pandemic has had an impact on the market for treating UTIs in terms of project delays in several nations. The global urinary tract infection testing market has been hampered by supply chain constraints, jammed logistics due to lockdowns, and other regulatory restrictions
• According to a report published in the ADIAN Journal in December 2020, there was a large decline in urinary tract infection (UTI) diagnoses due to the COVID-19 pandemic. When persons with COVID-19 become infected with COVID-19 virus the pandemic drastically altered primary care

Key Findings of the Study

• Based on infection type, the cystitis sub-segment emerged as the global leader in 2021 and the pyelonephritis sub-segment is anticipated to be the fastest growing during the forecast period
• Based on test type, the urinalysis sub-segment emerged as the global leader in 2021 and is predicted to witness the fastest growth in the upcoming years
• Based on infection type, the cystitis sub-segment emerged as the global leader in 2021 and the pyelonephritis sub-segment is anticipated to be the fastest growing during the forecast period
• Based on end-user, the hospitals sub-segment emerged as the global leader in 2021 and the diagnostic laboratories sub-segment is expected to be the fastest growing during the forecast period
• Based on test kit, the laboratory test kit sub-segment emerged as the global leader in 2021 and is predicted to be the fastest growing during the forecast period
• Based on region, the North America market registered the highest market share in 2021 and is projected to maintain its position during the forecast period